NICE has issued new draft guidance that does not recommend lenalidomide (Revlimid) for treating patients with myelodysplastic syndrome.  For more details, go to http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsOnANewTreatmentForMyelodysplasticSyndromes...